Compare VERI & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERI | CRBP |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.9M | 147.4M |
| IPO Year | 2017 | 2014 |
| Metric | VERI | CRBP |
|---|---|---|
| Price | $1.81 | $10.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $8.20 | ★ $45.60 |
| AVG Volume (30 Days) | ★ 2.6M | 201.7K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.36 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $92,637,000.00 | $4,822,272.00 |
| Revenue This Year | $20.56 | N/A |
| Revenue Next Year | $19.11 | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $1.29 | $4.64 |
| 52 Week High | $9.42 | $20.56 |
| Indicator | VERI | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 29.41 | 62.24 |
| Support Level | $1.29 | $9.86 |
| Resistance Level | $3.12 | $11.64 |
| Average True Range (ATR) | 0.22 | 0.69 |
| MACD | -0.08 | 0.09 |
| Stochastic Oscillator | 12.53 | 83.54 |
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has a presence in the United States, the United Kingdom, France, Australia, Israel, and India.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.